NTLA · NASDAQ
Intellia Therapeutics, Inc.
$12.10 -0.21 (-1.75%)
Company overview
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemophilia A and hemophilia B, hyperoxaluria Type 1, and alpha-1 antitrypsin deficiency. Its ex vivo pipeline includes NTLA-5001 for the treatment of acute myeloid leukemia; and proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune disorders. In addition, it offers tools comprising the Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. Intellia Therapeutics, Inc.
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Market cap
- $1.7B
- Employees
- 403
- Headquarters
- Cambridge, MA
- Website
- intelliatx.com
- CEO
- John Leonard
- Listed
- May 6, 2016
- P/E
- -3.36
- Dividend yield
- 0.00%
Company financials
- Revenue
- $66.1M
- Gross profit
- -$21.1M
- Operating income
- -$421M
- EBITDA
- -$398M
- Net income
- -$395M
- EPS
- -$3.54
- Total assets
- $759M
- Total debt
- $80.5M
- Gross margin
- -31.89%
- Net margin
- -597.04%
- Earnings yield
- -29.72%
NTLA
1D
NASDAQ
O12.26H12.53L11.90C12.32+0.46 (+3.84%)Vol2.44M
News